ITeos Therapeutics Announces Appointment of Dr. Christophe Quéva as Chief Scientific Officer

Share Article

ITeos Therapeutics SA announced today the appointment of Christophe Quéva Ph.D., as the company's chief scientific officer. Dr. Quéva is a key addition to the scientific strength and direction for the company’s ambitions to expand its pipeline of immunomodulators for cancer therapies.

ITeos Therapeutics SA announced today the appointment of Christophe Quéva Ph.D., as the company's chief scientific officer. Dr. Quéva is a key addition to the scientific strength and direction for the company’s ambitions to expand its pipeline of immunomodulators for cancer therapies.

Starting from his Ph.D. at the University of Lille, Dr. Quéva has pursued oncology, immunology and drug development, first with his postdoctoral studies at the Fred Hutchinson Cancer Research Center, followed by over 15 years of director level positions in oncology R&D at AstraZeneca, Amgen and Gilead Sciences. He has published numerous articles and patents in the field of cancer biology, immune therapy and drug discovery.

“We are extremely pleased to welcome Christophe to our team and benefit from his outstanding expertise and experience in the development and commercialization of new immuno-oncology drugs,” said Michel Detheux, iTeos Therapeutics’ CEO. “We are growing our immunomodulator discovery platform and adding partnerships with our new CSO as a key driver for both the selection and direction of our pipeline candidates in this highly competitive immuno-oncology space.”

About iTeos Therapeutics SA
Originating from a partnership between Ludwig Cancer Research and de Duve Institute at the Université Catholique de Louvain, iTeos Therapeutics SA (http://www.iteostherapeutics.com) is a private biotechnology company targeting the metabolism of the tumor microenvironment for the development of innovative immuno-oncology therapeutics. In December 2014, iTeos partnered with Pfizer Inc. for the development of its IDO1 and TDO2 drug candidates, as well as to discover and validate new targets involved in cancer immunosuppression. iTeos is currently expanding its pipeline’s programs to develop innovative immunomodulators for different cancer indications, with a focus on metabolism of tumor micro-environment.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Alfred Gray
Visit website